50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy
DENVER, May 12, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year’s ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria.
MRIdian-focused presentations and posters, submitted by MRIdian clinical teams from across the globe and accepted as part of ESTRO’s Scientific Sessions, highlight MRIdian’s clinical value in treating various cancers, including pancreatic, prostate, liver, rectal, cervical, and central/ultracentral lung tumors. Additional topics highlighted include patient satisfaction, cost/benefit analysis, and single-day MRIdian treatments.
ViewRay will host a lunch symposium on Saturday, May 13, from 13:00 – 14:00 CEST at the Messe Congress Center, Lehar 1-2-3 titled, “MRIdian A3i™*: Transforming MR-guided Radiation Therapy.” The presentation will be given by Drs. Luca Boldrini, Lorenzo Placidi (Policlinico A. Gemelli), Philip Camilleri, and James Good (GenesisCare Oxford). MRIdian A3i* adds new treatment delivery features that enhance on-table adaptive workflow efficiency and expand clinical utility. This symposium will highlight new MRIdian A3i* features, including MRI imaging sequences, automated workflow steps, on-table auto-contouring tools, multiplanar tissue tracking and automated beam gating, and the ability for clinicians to work collaboratively during patient treatments.
MRIdian A3i* introduces the 4th generation of real-time tissue tracking with automatic beam gating, now with multiplanar tracking and gating. This month marks 11 years since the introduction of these capabilities, for which MRIdian was the first system to offer real-time tissue tracking with automatic beam control following FDA clearance in May 2012.
Visitors to ViewRay’s booth #260 can see demonstrations and presentations of MRIdian A3i* and the new BrainTx package. They can also hear first-hand experience from clinicians around the world highlighting MRIdian’s benefits in treating a variety of cancers including:
Saturday, May 13
- Sarcoma treatments and high-value DWI with MRIdian A3i*: Kujtim Latifi, PhD, Moffitt Cancer Center
- Single fraction liver treatments with MRIdian SMART: Stefanie Corradini, MD, Ludwig Maximilian University
Sunday, May 14
- MRIdian A3i* BrainTx™ first experiences: Rupesh Kotecha, MD, Miami Cancer Institute
- MRIdian solutions for prostate, lung, and liver: Juliane Hörner-Rieber, MD, Heidelberg University Hospital
- MRIdian empowers Radiation therapist-driven treatment workflows: Moran Debby, RTT, Assuta Medical Center
Monday, May 15
- MRIdian solutions for pancreas cancer: Olivier Riou, MD, PhD, Institut du Montpellier
- Intensified total neoadjuvant rectum treatments on MRIdian: Thierry Gevaert, PhD, Universitair Ziekenhuis Brussel
The MRIdian system provides oncologists with outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions without relying on implanted markers. MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins by providing continuous real-time tracking of the target and organs at risk. This allows for delivering the prescribed dose to the target while sparing surrounding healthy tissue and critical structures. This results in minimizing toxicities typically associated with conventional radiation therapy.
To date, over 31,000 patients have been treated with MRIdian. Currently, 61 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/mridian-treatment-centers/
* MRIdian A3i features are only available for sale in the United States and other limited geographies. MRIdian A3i functions are intended for educational demonstration purposes only and cannot be made available until applicable medical device regulations are met.
Disclaimer:
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.
Safety Statement
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay’s financial guidance for the full year 2023, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue, the timing of delivery of ViewRay’s products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
SOURCE ViewRay, Inc.
